No title provided

Grant number: 335527

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $3,008,122.08
  • Funder

    Academy of Finland
  • Principal Investigator

    Paula A-M Eerola
  • Research Location

    Finland
  • Lead Research Institution

    University of Helsinki
  • Research Priority Alignment

    N/A
  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

At the University of Helsinki, high-quality research relevant for combatting the current coronavirus epidemic and mitigating its consequences is carried out on a wide front. The epidemic has challenged the societies on many levels and in inter-connected ways. Like the epidemic with its wide-spread societal effects, the research projects relevant for the epidemic cover many scientific fields throughout the University reflecting the diverse and high-quality research conducted at the University. In the research projects, the fight against the COVID-19 epidemic and reduction and/or prevention of its consequences is approached from multiple perspectives, often in a multi-/interdisciplinary way. The perspectives range from societal and educational to environmental and natural science-related, and naturally also to medical and health.

Publicationslinked via Europe PMC

Convalescent plasma therapy for COVID-19 - Donor selection strategies and establishment of a plasma bank.

Dynamin independent endocytosis is an alternative cell entry mechanism for multiple animal viruses.

Martini 3 OliGo̅mers: A Scalable Approach for Multimers and Fibrils in GROMACS.

Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients' variants.

Whole Blood as a Sample Matrix in Homogeneous Time-Resolved Assay-Förster Resonance Energy Transfer-Based Antibody Detection.

Mucosal-Associated Invariant T Cells are not susceptible in vitro to SARS-CoV-2 infection but accumulate into the lungs of COVID-19 patients.

Surfactant Proteins SP-B and SP-C in Pulmonary Surfactant Monolayers: Physical Properties Controlled by Specific Protein-Lipid Interactions.

Protein Crowding and Cholesterol Increase Cell Membrane Viscosity in a Temperature Dependent Manner.

SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.